ORIGINAL RESEARCH article
Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1653538
Gallic Acid Potentiates the Anticancer Efficacy of Cisplatin in Ovarian Cancer Cells through Modulation of the PI3K/AKT/mTOR and CXCL12/CXCR4 Signaling Pathways
Provisionally accepted
Jinlan Liang1,2
婷婷 陆1,2,3
Tiyan Shan2,3,4Huiting Liang1,2,3
Wenjie Wang2,3,4Zhijun Song5*
Yong Tang3,6,7*
Wang Qi1,2,3*- 1Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China
- 2Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning, China
- 3University Engineering Research Center of Oncolytict and Naosyster Development, Nanning, China
- 4Institute of Life Sciences, Guangxi Medical University, Nanning, China
- 5Guangxi Botanical Garden of Medicinal Plants, Nanning, China
- 6Department of Urology, Guangxi Medical University Cancer Hospital, Nanning, China
- 7State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study investigates the antitumor effects of gallic acid (GA) on ovarian cancer cells and its potential synergistic therapeutic effects with cisplatin (DDP) through modulation of the PI3K/AKT/mTOR signaling pathway. Systematic evaluations were conducted using both in vitro cell experiments and in vivo animal models to assess the impact of GA alone and in combination with DDP on ovarian cancer cell proliferation, apoptosis, and related signaling pathways. The results demonstrate that GA significantly inhibits the proliferation of ovarian cancer cells and enhances the anticancer effects of DDP by regulating the PI3K/AKT/mTOR signaling pathway. In in vivo experiments, the combination of GA and DDP significantly inhibits tumor growth and prolongs survival in a mouse model of ovarian cancer without apparent toxicity to vital organs. This study provides scientific evidence for the potential use of GA as an adjuvant drug in ovarian cancer treatment.
Keywords: Gallic Acid, ovarian cancer, Cisplatin, PI3K/AKT/mTORsignaling pathway, CXCL12/CXCR4 Signaling Pathways, Synergisticeffect
Received: 25 Jun 2025; Accepted: 29 Aug 2025.
Copyright: © 2025 Liang, 陆, Shan, Liang, Wang, Song, Tang and Qi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhijun Song, Guangxi Botanical Garden of Medicinal Plants, Nanning, China
Yong Tang, University Engineering Research Center of Oncolytict and Naosyster Development, Nanning, China
Wang Qi, Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.